Dopamine agonists (DA) are therapeutic agents that are commonly used in the treatment of
Parkinson's disease (PD). They can reduce undesired motor fluctuations and delay the …

Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized
by selective degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Dopamine receptor agonists provide a viable alternative or adjunct to levodopa therapy in
Parkinson's disease and are associated with fewer motor complications and dyskinesia …

Introduction: Prolonged administration of l-3, 4-dihydroxyphenylalanine (l–DOPA) for
Parkinson's disease (PD) is hampered by motor complications related to the progressive …

After more than 40 years of clinical use, levodopa (LD) remains the gold standard of
symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other …

Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …

Parkinson׳ s disease (PD) is chronic progressive neurodegenerative disorder characterized
by profound loss of dopaminergic neurons in the nigrostriatal pathway. It is recognized by …

Parkinsons disease (PD) is a progressive, disabling neurodegenerative disorder with onset
of motor and non-motor features. Both reduce quality of life of PD patients and cause …

Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs
have been considered as the main therapy against motor symptoms of Parkinson's disease …